• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植后条件生存、病因特异性死亡率和晚期死亡率的危险因素。
J Natl Cancer Inst. 2020 Nov 1;112(11):1153-1161. doi: 10.1093/jnci/djaa022.
2
Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.异基因造血干细胞移植后长期存活者的晚期死亡率及死亡原因
Biol Blood Marrow Transplant. 2016 Sep;22(9):1702-1709. doi: 10.1016/j.bbmt.2016.05.019. Epub 2016 May 28.
3
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.异基因造血细胞移植后的晚期死亡率及长期存活者的功能状态:来自骨髓移植幸存者研究的报告
Blood. 2007 Nov 15;110(10):3784-92. doi: 10.1182/blood-2007-03-082933. Epub 2007 Aug 1.
4
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后的长期生存和晚期死亡。
J Clin Oncol. 2011 Jun 1;29(16):2230-9. doi: 10.1200/JCO.2010.33.7212. Epub 2011 Apr 4.
5
Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.长期造血细胞移植受者的相对生存率接近普通人群水平。
Biol Blood Marrow Transplant. 2009 Oct;15(10):1323-30. doi: 10.1016/j.bbmt.2009.06.014. Epub 2009 Aug 3.
6
Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.造血细胞移植合并症指数(HCT-CI)可预测老年异基因移植受者的不良事件和总生存期。
J Geriatr Oncol. 2014 Jul;5(3):238-44. doi: 10.1016/j.jgo.2014.04.003. Epub 2014 Jun 2.
7
Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.异基因造血细胞移植后1年无病患者的长期生存:389例连续患者的单中心分析
Bone Marrow Transplant. 2018 May;53(5):576-583. doi: 10.1038/s41409-017-0076-2. Epub 2018 Jan 15.
8
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.在慢性髓性白血病慢性期 1 期行清髓性异基因造血细胞移植后的 5 年无病生存者中复发和晚期死亡。
J Clin Oncol. 2010 Apr 10;28(11):1888-95. doi: 10.1200/JCO.2009.26.7757. Epub 2010 Mar 8.
9
Primary Preventive Care of Hematopoietic Stem Cell Transplantation Survivors: Time to Educate and Empower Recipients and Providers.造血干细胞移植受者的初级预防保健:是时候对受者和提供者进行教育和赋权了。
Transplant Cell Ther. 2023 Feb;29(2):131.e1-131.e6. doi: 10.1016/j.jtct.2022.10.028. Epub 2022 Nov 4.
10
High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后青少年和年轻成人幸存者后续随访终止的可能性较高。
Blood Adv. 2019 Feb 12;3(3):397-405. doi: 10.1182/bloodadvances.2018026039.

引用本文的文献

1
Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study.接受实体器官移植的造血细胞移植受者实体器官移植失败和死亡的风险因素:一项国际血液和骨髓移植研究中心及器官获取与移植网络的回顾性研究。
Transplantation. 2025 Jun 23. doi: 10.1097/TP.0000000000005397.
2
Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.癌症治疗后的心血管问题:证据空白与专家小组建议
JACC CardioOncol. 2025 Jan 21;7(1):1-19. doi: 10.1016/j.jaccao.2024.06.006. eCollection 2025 Jan.
3
Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia.急性白血病异基因造血细胞移植后2年生存者的长期预后
Hemasphere. 2024 Oct 22;8(10):e70026. doi: 10.1002/hem3.70026. eCollection 2024 Oct.
4
Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.造血干细胞移植患者的心血管考虑因素。
Curr Treat Options Oncol. 2024 Aug;25(8):1027-1037. doi: 10.1007/s11864-024-01240-1. Epub 2024 Jul 25.
5
Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.免疫抑制治疗再生障碍性贫血后出现复发和向骨髓增生异常综合征和急性髓系白血病转化的情况比异基因造血干细胞移植更为常见,对生存有负面影响。
Ann Hematol. 2024 Mar;103(3):749-758. doi: 10.1007/s00277-024-05621-2. Epub 2024 Jan 20.
6
Risky health behaviors and subsequent late mortality after blood or marrow transplantation: a BMTSS report.血液或骨髓移植后危险的健康行为与随后的晚期死亡:BMTSS 报告。
Blood Adv. 2023 Nov 28;7(22):7028-7044. doi: 10.1182/bloodadvances.2023010633.
7
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.≥1 年异基因造血细胞移植幸存者的长期结局中的种族和社会经济差异:CIBMTR 分析。
Transplant Cell Ther. 2023 Nov;29(11):709.e1-709.e11. doi: 10.1016/j.jtct.2023.07.013. Epub 2023 Jul 22.
8
Racial disparities in conditional survival of patients with bladder cancer: a population-based study.膀胱癌患者条件生存的种族差异:一项基于人群的研究。
BMC Urol. 2023 Jul 18;23(1):122. doi: 10.1186/s12894-023-01293-8.
9
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy.造血细胞移植或免疫抑制治疗后至少存活 1 年的重型再生障碍性贫血患者的条件生存和标准化死亡率比。
Haematologica. 2023 Dec 1;108(12):3298-3307. doi: 10.3324/haematol.2023.282781.
10
Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.造血干细胞移植受者的心血管事件:系统评价和荟萃分析。
Bone Marrow Transplant. 2023 May;58(5):478-490. doi: 10.1038/s41409-023-01928-2. Epub 2023 Feb 27.

本文引用的文献

1
Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.造血干细胞移植存活者的心血管疾病预测。
Blood Adv. 2018 Jul 24;2(14):1756-1764. doi: 10.1182/bloodadvances.2018019117.
2
Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.胰腺腺癌中、长期幸存者的死因和条件生存估计。
JAMA Oncol. 2018 Aug 1;4(8):1129-1130. doi: 10.1001/jamaoncol.2018.2442.
3
Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study.血液恶性肿瘤患者造血细胞移植后的认知功能:一项前瞻性纵向研究的结果。
J Clin Oncol. 2018 Feb 10;36(5):463-475. doi: 10.1200/JCO.2017.74.2270. Epub 2017 Dec 18.
4
Reduction in Late Mortality after Childhood Cancer.儿童癌症后晚期死亡率的降低
N Engl J Med. 2016 Jul 21;375(3):290-2. doi: 10.1056/NEJMc1604184.
5
Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time.条件生存:一个提供关于预后随时间变化的信息的有用概念。
Clin Cancer Res. 2015 Apr 1;21(7):1530-6. doi: 10.1158/1078-0432.CCR-14-2154.
6
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.共病年龄指数:异基因造血细胞移植前生物学年龄的一种临床测量方法。
J Clin Oncol. 2014 Oct 10;32(29):3249-56. doi: 10.1200/JCO.2013.53.8157. Epub 2014 Aug 25.
7
Prevalence of hematopoietic cell transplant survivors in the United States.美国造血细胞移植幸存者的患病率。
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501. doi: 10.1016/j.bbmt.2013.07.020. Epub 2013 Jul 30.
8
Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies.血液系统恶性肿瘤患者自体造血细胞移植后的条件生存和病因特异性死亡率。
Leukemia. 2013 Apr;27(5):1139-45. doi: 10.1038/leu.2012.311. Epub 2012 Nov 7.
9
Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.自体造血细胞移植后充血性心力衰竭的发生率和预测因素。
Blood. 2011 Dec 1;118(23):6023-9. doi: 10.1182/blood-2011-06-358226. Epub 2011 Oct 5.
10
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后的长期生存和晚期死亡。
J Clin Oncol. 2011 Jun 1;29(16):2230-9. doi: 10.1200/JCO.2010.33.7212. Epub 2011 Apr 4.

异基因造血细胞移植后条件生存、病因特异性死亡率和晚期死亡率的危险因素。

Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.

机构信息

Department of Population Sciences, City of Hope, Duarte, CA, USA.

Department of Computational and Quantitative Medicine, City of Hope, CA, USA.

出版信息

J Natl Cancer Inst. 2020 Nov 1;112(11):1153-1161. doi: 10.1093/jnci/djaa022.

DOI:10.1093/jnci/djaa022
PMID:32044955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7669225/
Abstract

BACKGROUND

Long-term mortality after hematopoietic cell transplantation (HCT) is conventionally calculated from the time of HCT, ignoring temporal changes in survivors' mortality risks. Conditional survival rates, accounting for time already survived, are relevant for optimal delivery of survivorship care but have not been widely quantified. We estimated conditional survival by elapsed survival time in allogeneic HCT patients and examined cause-specific mortality.

METHODS

We calculated conditional survival rates and standardized mortality ratio for overall and cause-specific mortality in 4485 patients who underwent HCT for malignant hematologic diseases at a large transplant center during 1976-2014. Statistical tests were two-sided.

RESULTS

The 5-year survival rate from HCT was 48.6%. After surviving 1, 2, 5, 10, and 15 years, the subsequent 5-year survival rates were 71.2%, 78.7%, 87.4%, 93.5%, and 86.2%, respectively. The standardized mortality ratio was 30.3 (95% confidence interval [CI] = 29.2 to 35.5). Although the standardized mortality ratio declined in longer surviving patients, it was still elevated by 3.6-fold in survivors of 15 years or more (95% CI = 3.0 to 4.1). Primary disease accounted for 50% of deaths in the overall cohort and only 10% in 15-year survivors; the leading causes of nondisease-related mortality were subsequent malignancy (26.1%) and cardiopulmonary diseases (20.2%). We also identified the risk factors for nondisease-related mortality in 1- and 5-year survivors.

CONCLUSION

Survival probability improves the longer patients survive after HCT. However, HCT recipients surviving 15 years or more remain at elevated mortality risk, largely because of health conditions other than their primary disease. Our study findings help inform preventive and interventional strategies to improve long-term outcomes after allogeneic HCT.

摘要

背景

造血细胞移植(HCT)后的长期死亡率通常从 HCT 时间开始计算,忽略了幸存者死亡风险的时间变化。考虑到已经存活的时间,条件生存率与生存护理的最佳提供相关,但尚未广泛量化。我们通过异基因 HCT 患者的已存活时间来估计条件生存率,并检查了特定原因的死亡率。

方法

我们计算了 1976 年至 2014 年在一家大型移植中心接受恶性血液疾病 HCT 的 4485 例患者的总体和特定原因死亡率的条件生存率和标准化死亡率比。统计检验为双侧。

结果

HCT 后的 5 年生存率为 48.6%。在存活 1、2、5、10 和 15 年后,随后的 5 年生存率分别为 71.2%、78.7%、87.4%、93.5%和 86.2%。标准化死亡率比为 30.3(95%置信区间[CI] = 29.2 至 35.5)。尽管在存活时间较长的患者中,标准化死亡率比有所下降,但在存活 15 年或更长时间的患者中,仍高出 3.6 倍(95%CI = 3.0 至 4.1)。原发性疾病占总队列死亡人数的 50%,而在 15 年幸存者中仅占 10%;非疾病相关死亡的主要原因是随后的恶性肿瘤(26.1%)和心肺疾病(20.2%)。我们还确定了 1 年和 5 年幸存者中非疾病相关死亡的危险因素。

结论

HCT 后患者存活时间越长,生存概率越高。然而,存活 15 年或更长时间的 HCT 受者仍面临较高的死亡风险,主要是由于原发性疾病以外的健康状况。我们的研究结果有助于为异基因 HCT 后改善长期结果提供预防和干预策略。